Quarterly ResultAug 11, 2026, 04:16 PM
LENZ Q2 2026 Revenue $5.5M; Net Loss $31.9M
AI Summary
LENZ Therapeutics reported Q2 2026 total revenue of $5.5 million, including $1.7 million from VIZZ product sales, which increased 9% over Q1 2026. The company posted a net loss of $31.9 million for the quarter. Key commercial highlights include strong patient persistence for VIZZ, with over 60% of ePharmacy patients purchasing multiple monthly packs, and the launch of a telehealth channel and national TV campaign in July 2026. LENZ also advanced its global strategy with new international partnerships and regulatory submissions for VIZZ in the UK, Canada, Australia, New Zealand, and Greater China.
Key Highlights
- Q2 2026 total revenue was $5.5 million.
- Q2 2026 net loss was $31.9 million.
- Product sales reached $1.7 million, a 9% increase over Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $220.0 million.
- Over 60% of ePharmacy VIZZ patients purchased multiple monthly packs.
- Launched telehealth prescribing option and national TV campaign in July 2026.
- Secured multiple international partnerships and regulatory submissions for VIZZ.
Price Impact
More from LENZ